RxDoctor Payments Data

Ryan Knape

Physician Assistant · Adrian, MINPI 1841535762

Payments from drug & device makers

$820in general payments, 2019–2025

Across 42 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$241
  • AbbVie$233
  • GSK$97
  • E.r. Squibb & Sons, L.L.C.$78
  • Pfizer$71
  • Otsuka America Pharmaceutical, Inc.$50
  • plus $50 from 2 others

What the payments were for

  • Food & beverage$820100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$820 in reported general payments places this provider in the 70th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$61,879
Medicare patients
97
Services billed
2,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide35$42,239
EliquisApixaban45$42,041
OzempicSemaglutide41$38,595
JanuviaSitagliptin Phosphate26$32,512
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$29,450
Tresiba Flextouch U-200Insulin Degludec17$22,234
XareltoRivaroxaban19$18,391
Soliqua 100-33Insulin Glargine/Lixisenatide21$16,943
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$15,069
MounjaroTirzepatide14$14,600
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$13,746
JardianceEmpagliflozin12$12,656
SymbicortBudesonide/Formoterol Fumarate28$7,397
FarxigaDapagliflozin Propanediol11$6,298
Qvar RedihalerBeclomethasone Dipropionate12$5,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$42,04145 claims
Novo NordiskOzempic$241$38,59541 claims
GSKTrelegy Ellipta$97$29,45043 claims
AbbVieSynthroid$233$1,03611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Adrian

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →